Plain-English translation of NCT06556732 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called eplerenone, taken as a daily pill, can help prevent atrial fibrillation (an irregular heart rhythm) from coming back in people whose hearts have structural issues. You would receive this medication alongside your other heart medicines. The study wants to see if this treatment reduces how often the irregular heartbeat returns after it has been corrected.
Atrial fibrillation often comes back even after doctors successfully correct it, which can be frustrating and risky for patients. Researchers believe this medication might help keep the heart rhythm stable and prevent the problem from recurring, which would improve quality of life for people with structural heart disease.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be assigned to either receive the new medication plus your standard heart medicines, or to continue with standard medicines alone. Both groups will be monitored to see how often the irregular heartbeat returns. The study involves 100 patients total and takes place at a hospital cardiology department where your heart rhythm will be tracked over time.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Egypt
Phase
Safety & dosing
Sponsor
Assiut University
Enrollment target
~100 participants
Started
August 2024
Primary completion
August 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
20 Years – 70 Years
Last updated on clinicaltrials.gov in August 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.